Attached files
file | filename |
---|---|
EX-32 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - QUANTRX BIOMEDICAL CORP | ex32.htm |
10-K/A - AMENDMENT NO. 1 TO FORM 10-K - QUANTRX BIOMEDICAL CORP | qtxb10ka_dec312016.htm |
Exhibit 31
CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER PURSUANT
TO EXCHANGE ACT RULE 13A-14(A)
I, Shalom Hirschman, certify that:
1. I have reviewed this report on Form
10-K/A of QuantRx Biomedical Corporation;
2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made,
not misleading with respect to the period covered by this
report;
3. Based on my knowledge, the financial
statements, and other financial information included in this
report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;
4. The registrant’s other certifying
officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such
disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under my supervision, to
ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to me by
others within those entities, particularly during the period in
which this report is being prepared;
(b) Designed such
internal control over financial reporting, or caused such internal
control over financial reporting to be designed under my
supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;
(c) Evaluated the
effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the
end of the period covered by this report based on such evaluation;
and
(d) Disclosed in this
report any change in the registrant's internal control over
financing reporting that occurred during the registrant's most
recent fiscal quarter (the registrant's fourth fiscal quarter in
the case of an annual report) that
has materially affected,
or is reasonably likely to materially affect,
the registrant's internal control over financial
reporting; and
5. The registrant’s other certifying
officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of the registrant's
board of directors (or persons performing the equivalent
function):
(a) All significant
deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record,
process, summarize and report financial information;
and
(b) Any fraud, whether or
not material, that involves management or other employees who have
a significant role in the registrant's internal control over
financial reporting.
Date: October 5, 2017
|
/s/ Shalom Hirschman
|
|
|
Shalom Hirschman
Principal Executive and Financial Officer
|
|